Asia Pacific Active Pharmaceutical Ingredients Market (2021 to 2027) – by Synthesis, Manufacturing Process, Therapeutic Application, Drug Type and Country – ResearchAndMarkets.com

12-Mar-2021 Intellasia | BusinessWire | 10:19 PM Print This Post

DUBLIN--(BUSINESS WIRE)--The "Asia Pacific Active Pharmaceutical Ingredients (API) Market 2021-2027 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Country: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.


Asia Pacific active pharmaceutical ingredients (API) market will grow by 9.0% annually with a total addressable market cap of $636.1 billion over 2021-2027 driven by the rising need for medicine and pharmaceutical agents amid the COVID-19 pandemic.

This report is based on a comprehensive research of the entire Asia Pacific API market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2020 and provides forecast from 2021 till 2027 with 2020 as the base year.

Key Players:

  • AbbVie Inc.
  • Astrazeneca
  • Aurobindo Pharma Ltd.
  • BASF
  • Bayer AG
  • Boehringer Ingelheim
  • Dr. Reddy's Laboratories
  • F. Hoffmann-La Roche
  • GlaxoSmithKline plc
  • Lonza Group
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

In-depth qualitative analyses include identification and investigation of the following aspects:

  • Market Structure
  • Growth Drivers
  • Restraints and Challenges
  • Emerging Product Trends & Market Opportunities
  • Porter's Five Forces

The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific API market in every aspect of the classification from perspectives of Synthesis, Manufacturing Process, Therapeutic Application, Drug Type, and Country.

For each key country, detailed analysis and data for annual revenue are available for 2017-2027. The breakdown of key national markets by Synthesis, Manufacturing Process, and Therapeutic Application over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in Asia Pacific API market are assayed quantitatively and qualitatively through a Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Topics Covered:

1 Introduction

2 Market Overview and Dynamics

2.1 Market Size and Forecast

2.1.1 Impact of COVID-19 on World Economy

2.1.2 Impact of COVID-19 on the Market

2.2 Major Growth Drivers

2.3 Market Restraints and Challenges

2.4 Emerging Opportunities and Market Trends

2.5 Porter's Five Forces Analysis

3 Segmentation of Asia Pacific Market by Synthesis

3.1 Market Overview by Synthesis

3.2 Synthetic API

3.2.1 Branded Synthetic API

3.2.2 Generic Synthetic API

3.3 Biotech API

3.3.1 Biotech API by Drug Type

3.3.1.1 Monoclonal Antibodies

3.3.1.2 Recombinant Proteins

3.3.1.3 Vaccines

3.3.1.4 Other Biotech APIs

3.3.2 Biotech API by Customer Base

3.3.2.1 Innovative Biologic API

3.3.2.2 Generic Biosimilar API

3.3.3 Biotech API by Expression Technology

3.3.3.1 Mammalian Expression

3.3.3.2 Microbial Expression

3.3.3.3 Yeast Expression

3.3.3.4 Insect Expression

3.3.3.5 Other Expression Technologies

3.4 HPAPI

3.4.1 Branded HPAPI

3.4.2 Generic HPAPI

4 Segmentation of Asia Pacific Market by Manufacturing Process

4.1 Market Overview by Manufacturing Process

4.2 Captive Manufacturing

4.2.1 Branded Captive API

4.2.2 Generic Captive API

4.3 Merchant Manufacturing

4.3.1 Merchant Manufacturing by Drug Type

4.3.1.1 Branded Merchant API

4.3.1.2 Generic Merchant API

4.3.2 Merchant Manufacturing by Drug Synthesis

4.3.2.1 Merchant Synthetic API

4.3.2.2 Merchant Biotech API

5 Segmentation of Asia Pacific Market by Therapeutic Application

5.1 Market Overview by Therapeutic Application

5.2 Infectious Diseases

5.3 Oncology

5.4 Ophthalmology

5.5 Cardiovascular Disorders

5.6 Central Nervous System

5.7 Pulmonary Disorders

5.8 Orthopedics

5.9 Other Applications

6 Segmentation of Asia Pacific Market by Drug Type

6.1 Market Overview by Drug Type

6.2 Branded Prescription Drugs

6.3 Generic Prescription Drugs

6.4 OTC Drugs

7 Asia-Pacific Market 2020-2027 by Country

7.1 Overview of Asia-Pacific Market

7.2 China

7.3 Japan

7.4 India

7.5 Australia

7.6 South Korea

7.7 Rest of APAC Region

8 Competitive Landscape

8.1 Overview of Key Vendors

8.2 New Product Launch, Partnership, Investment, and M&A

8.3 Company Profiles

9 Investing in Asia Pacific Market: Risk Assessment and Management

9.1 Risk Evaluation of Asia Pacific Market

9.2 Critical Success Factors (CSFs)

For more information about this report visit https://www.researchandmarkets.com/r/xcolm5


Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

 

Category: BusinessWire, PRAsia

Print This Post

Comments are closed.